Curis vs Inhibrx Biosciences
CRIS and INBX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRIS and INBX compare
Inhibrx Biosciences is the larger company, worth 1318 times as much as Curis ($1.2B against $930K).
Curis scores higher on the StockData Score (5 against 1 for Inhibrx Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRIS | INBX |
|---|---|---|
| Size and price | ||
| Market cap | $930K | $1.2B |
| Share price | $0.445 | $83.30 |
| Change, 1 year | −98.2% | 13.6% |
| Change, 5 years | −100.0% | 92.3% |
| Beta (5Y) | 1.90 | 1.70 |
| Employees | 24 | 110 |
| StockData Score | ||
| Total score | 5 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.4× | – |
| FCF yield | – | −10.8% |
| Growth | ||
| Revenue growth, 5Y average | −2.7% (better) | −36.8% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −5.9× |
| Current ratio | 0.43 | 7.58 (better) |
| Altman Z-score | −98.36 | −0.76 (better) |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 32.1% | 97.4% |
| Held by insiders | 20.4% | 35.4% |
| Insider net buying, 12 months | $5.5K | $6.1M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 61.8% | 35.7% |
Go deeper
- CRIS stock overview
- CRIS income statement
- CRIS valuation and score
- INBX stock overview
- INBX income statement
- INBX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.